載入...
Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation
Cancer treatments often require combinations of molecularly targeted agents to be effective. mTORi (rapamycin) and HDACi (MS-275/entinostat) inhibitors have been shown to be effective in limiting tumor growth, and here we define part of the cooperative action of this drug combination. More than 60 h...
Na minha lista:
| 發表在: | Mol Cancer Ther |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5587368/ https://ncbi.nlm.nih.gov/pubmed/28522584 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0171 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|